newsfilter
← Latest News
GlobeNewswire·

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

  • TScan Therapeutics, Inc. (NASDAQ: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Time.
  • The presentation will occur as a hybrid session with an analyst-led Q&A at the Boston Marriott Copley Place in Boston, MA.
  • A webcast of the event will be available on the "Events and Presentations" section of ir.tscan.com, with an archived replay accessible for 90 days post-event.
  • TScan is developing TCR-engineered T cell therapies for cancer, with its lead candidate targeting hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation in the ALLOHA™ Phase 1 heme trial.
  • The company is developing TCR-T candidates for solid tumors and advancing methods for in vivo engineering.
  • TScan is applying its target discovery platform to identify novel targets for T cell-mediated autoimmune disorders.
  • Investor inquiries can be directed to Troy Neubecker at 857-399-9517 or tneubecker@tscan.com.
  • Media inquiries can be directed to Caileigh Dougherty at 857-399-9890 or cdougherty@tscan.com.